Ault Milton C III's Form 4 filing
Alzamend Neuro, Inc. (ALZN) · filed May 14, 2025
- Accession no.
- 0001214659-25-007625
- Filed
- May 14, 2025
- Trade date
- May 12, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $6.20K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Ault Milton C IIICIK 0001212502 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 12, 2025 | Common Stock | SSaleDisposed | −1,213 | $5.06F1 | −$6,137.78 | 8,260 | Indirect | |
| May 12, 2025 | Common Stock | SSaleDisposed | −11 | $5.28 | −$58.08 | 1,843 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sale price of $5.0604. The range of sales prices on the transaction date was $5.0461 to $5.237 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price
Referenced by the price of 1 transaction in Table I.